Perceptive Advisors Stake in Oncomed Pharmaceuticals (OMED) Upped by $6.33 Million; Sector Gamma As Has Cut Bristol Myers Squibb Co (BMY) Position by $4.55 Million; Stock Value Rose

April 19, 2018 - By Stephen Andrade

Sector Gamma As decreased its stake in Bristol Myers Squibb Co (BMY) by 16.23% based on its latest 2017Q4 regulatory filing with the SEC. Sector Gamma As sold 74,600 shares as the company’s stock rose 2.38% while stock markets declined. The institutional investor held 385,006 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $23.59M, down from 459,606 at the end of the previous reported quarter. Sector Gamma As who had been investing in Bristol Myers Squibb Co for a number of months, seems to be less bullish one the $84.78B market cap company. The stock decreased 0.85% or $0.4468 during the last trading session, reaching $51.8532. About 11.19M shares traded or 28.91% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since April 19, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

Joseph Edelman increased its stake in Oncomed Pharmaceuticals Inc (OMED) by 152.42% based on its latest 2017Q4 regulatory filing with the SEC. Perceptive Advisors Llc bought 1.58M shares as the company’s stock declined 11.20% with the market. The hedge fund run by Joseph Edelman held 2.62 million shares of the health care company at the end of 2017Q4, valued at $10.75M, up from 1.04M at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Oncomed Pharmaceuticals Inc for a number of months, seems to be bullish on the $116.69M market cap company. The stock increased 0.99% or $0.03 during the last trading session, reaching $3.05. About 37,159 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 65.75% since April 19, 2017 and is downtrending. It has underperformed by 77.30% the S&P500.

Since December 12, 2017, it had 1 insider buy, and 1 sale for $85,985 activity. On Friday, December 15 Samuels Theodore R. II bought $249,187 worth of Bristol-Myers Squibb Company (NYSE:BMY) or 4,000 shares.

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 12 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 80 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Friday, September 15. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Jefferies on Monday, February 26. The rating was maintained by Citigroup on Tuesday, September 20 with “Buy”. The company was downgraded on Friday, August 5 by Morgan Stanley. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Hold” rating given on Friday, September 22 by Piper Jaffray. The rating was upgraded by Morgan Stanley to “Overweight” on Thursday, February 15. The stock has “Outperform” rating by Leerink Swann on Monday, October 23. Piper Jaffray maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Thursday, October 26. Piper Jaffray has “Hold” rating and $60.0 target. Deutsche Bank maintained it with “Hold” rating and $52 target in Friday, October 28 report. Citigroup maintained the stock with “Buy” rating in Friday, February 16 report.

Sector Gamma As, which manages about $594.94M US Long portfolio, upped its stake in Astrazeneca Plc (NYSE:AZN) by 156,100 shares to 896,771 shares, valued at $31.12M in 2017Q4, according to the filing. It also increased its holding in Radius Health Inc (NASDAQ:RDUS) by 13,000 shares in the quarter, for a total of 52,173 shares, and has risen its stake in Laboratory Corp Amer Hldgs (NYSE:LH).

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on April, 26 before the open. They expect $0.84 EPS, 0.00% or $0.00 from last year’s $0.84 per share. BMY’s profit will be $1.37B for 15.43 P/E if the $0.84 EPS becomes a reality. After $0.68 actual EPS reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts 23.53% EPS growth.

Investors sentiment decreased to 0.94 in Q4 2017. Its down 0.09, from 1.03 in 2017Q3. It turned negative, as 72 investors sold BMY shares while 526 reduced holdings. 106 funds opened positions while 457 raised stakes. 1.11 billion shares or 0.48% more from 1.11 billion shares in 2017Q3 were reported. Rhumbline Advisers invested in 0.33% or 2.69M shares. Bb&T Securities Limited Company accumulated 559,328 shares. Westpac Bk Corporation accumulated 184,275 shares. Burke Herbert National Bank & Trust Tru holds 15,070 shares. Essex Financial Serv holds 1.15% or 78,820 shares. Spirit Of America Mngmt has 14,000 shares for 0.1% of their portfolio. Mitchell Mcleod Pugh & Williams, a Alabama-based fund reported 5,855 shares. Fjarde Ap invested in 458,947 shares or 0.43% of the stock. Teachers Retirement Of The State Of Kentucky invested 0.22% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Tci Wealth Advisors reported 0.87% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Moreover, Acadian Asset Ltd Liability Corporation has 0.01% invested in Bristol-Myers Squibb Company (NYSE:BMY). Winfield Associates accumulated 410 shares. Cypress Asset Mgmt Tx stated it has 0.66% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Hanseatic Mngmt Svcs reported 775 shares. Pinebridge Ltd Partnership owns 1,942 shares.

Perceptive Advisors Llc, which manages about $2.09 billion and $3.02B US Long portfolio, decreased its stake in Evolent Health Inc by 800,000 shares to 50,000 shares, valued at $615,000 in 2017Q4, according to the filing. It also reduced its holding in Tesaro Inc (NASDAQ:TSRO) by 259,279 shares in the quarter, leaving it with 129,372 shares, and cut its stake in Regenxbio Inc.

Investors sentiment increased to 1.62 in 2017 Q4. Its up 0.91, from 0.71 in 2017Q3. It is positive, as 3 investors sold OMED shares while 18 reduced holdings. 15 funds opened positions while 19 raised stakes. 19.21 million shares or 47.57% more from 13.02 million shares in 2017Q3 were reported. Primecap Mgmt Ca holds 5.57M shares. Millennium Mgmt Limited Liability Company holds 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 543,335 shares. Alpine Global Limited Liability holds 0.02% or 18,701 shares in its portfolio. Fny Managed Accounts Limited Liability accumulated 500 shares. Barclays Public Ltd Co reported 0% stake. Plante Moran Fincl Advsrs holds 0% or 380 shares. Virtu Fincl Lc invested in 41,395 shares. 303,971 are owned by Cannell Peter B And Communications. Bancorporation Of Montreal Can reported 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Bluecrest Capital Mngmt Ltd reported 32,382 shares or 0% of all its holdings. Vanguard Grp Inc Incorporated Inc has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 998,147 shares. Meeder Asset Mgmt owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 1,096 shares. Nj State Employees Deferred Compensation Plan accumulated 38,000 shares. Art Advsrs Ltd Liability Co holds 27,052 shares. Bridgeway Mngmt Incorporated stated it has 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED).

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. OncoMed Pharmaceuticals had 21 analyst reports since September 9, 2015 according to SRatingsIntel. Cantor Fitzgerald initiated the shares of OMED in report on Monday, April 18 with “Buy” rating. The company was initiated on Tuesday, April 12 by BMO Capital Markets. As per Friday, March 9, the company rating was maintained by H.C. Wainwright. Leerink Swann downgraded the shares of OMED in report on Monday, January 25 to “Mkt Perform” rating. The firm has “Buy” rating given on Wednesday, August 10 by Jefferies. JMP Securities maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Wednesday, March 9 with “Market Outperform” rating. As per Wednesday, September 9, the company rating was initiated by Jefferies. SunTrust maintained the stock with “Hold” rating in Friday, October 6 report. H.C. Wainwright initiated the shares of OMED in report on Thursday, September 22 with “Buy” rating. SunTrust maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Thursday, March 8. SunTrust has “Hold” rating and $3.0 target.

By1 Stephen Andrade